THT 2023: MCS device selection in HF patients - Where does counterpulsation fit?
This session focuses on the unique physiological effects of counterpulsation in advanced heart failure patients. Moreover, the session provides guidance on MCS selection based on underlying etiology, clinical phenotyping, and predictors for positive hemodynamic and clinical response. Finally, you will be presented with novel applications for counterpulsation in HF.
Program Agenda
- Introduction - Jerry D. Estep, MD, FACC, FASE, Cleveland Clinic Florida, Weston, FL
- Principles and Unique Physiological Effects Characteristic of Counterpulsation - Arvind Bhimaraj, MD, MPH, FACC, FHFSA, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX To watch this presentation, click here.
- Heart Failure Cardiogenic Shock – Unique Phenotype and tMCS Considerations - Rachna Kataria, MD - Lifespan Cardiovascular Institute – The Rhode Island and Miriam Hospitals, Providence, RI To watch this presentation, click here.
- Predictors for a Positive Hemodynamic & Clinical Response to Intra-aortic Counterpulsation - Reshad Garan, MD, MS, FACC, Beth Israel Deaconess Medical Center, Boston, MA To watch this presentation, click here.
- Novel Applications for Counterpulsation - Ran Lee, MD - Cleveland Clinic, Cleveland, OH To watch this presentation, click here.
- Discussion and Q&A
Comments 0
Login to view comments.
Click here to Login
